Tekturna
Product Images NDC 54868-5772

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tekturna (NDC 54868-5772). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of 150 mg Package Label (5772)

Packaging label for Tekturna 150 mg, distributed by Physicians Total Care, Inc., Tulsa, OK. The label includes lot number 0000, an expiration date of 01/60, and a barcode. Manufactured by Novartis Pharma GmbH, Wehr, Germany.*

FDA Label Image

Image Of 300 mg Package Label (6042)

Label for Tekturna 300 mg tablets distributed by Physicians Total Care, Inc., Tulsa, OK. The label includes lot number 0000 and expiration date 01/60. Manufactured by Novartis Pharma GmbH, Wehr, Germany, with visible barcode and NDC 54868-6042-0.*

FDA Label Image

Aliskiren Hemifumarate Structural Formula (Tekturna 01)

Chemical structure of the active ingredient in Tekturna, showing detailed molecular bonds and components including a carboxylic acid group and amide functionalities.*

FDA Label Image

Figure 1: The Impact Of Co-administered Drugs On The Pharmacokinetics Of Aliskiren. (Tekturna 02)

A forest plot chart illustrating the impact of various co-administered drugs on the pharmacokinetics (PK) of aliskiren, showing fold change and 90% confidence intervals for Cmax and AUC values. The chart categorizes drugs into CYP3A4/P-gp inhibitors, antihypertensives, and others, with corresponding dosage recommendations regarding dose adjustment or avoidance.*

FDA Label Image

Figure 2: The Impact Of Aliskiren On The Pharmacokinetics Of Co-administered Drugs. (Tekturna 03)

A pharmacokinetic impact chart showing the fold change and 90% confidence interval of co-administered drugs with aliskiren. It compares Cmax and AUC values for various antihypertensives and other drugs, indicating no dose adjustment needed for listed drugs, with a note on diminished furosemide effect after starting aliskiren.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.